Affymetrix, Inc.  

(Public, NASDAQ:AFFX)   Watch this stock  
Find more results for AFFX
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 6.25 - 10.00
Open     -
Vol / Avg. 0.00/805,269.00
Mkt cap 709.71M
P/E 2,237.82
Div/yield     -
EPS 0.00
Shares 73.58M
Beta 0.74
Inst. own 114%
Feb 3, 2015
Q4 2014 Affymetrix Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 17, 2014
Affymetrix Investor Day 2014 - Webcast
Oct 30, 2014
Q3 2014 Affymetrix Inc Earnings Call - Webcast
Oct 30, 2014
Q3 2014 Affymetrix Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 2.74% -4.94%
Operating margin 5.60% -3.80%
EBITD margin - 8.22%
Return on average assets 1.99% -3.11%
Return on average equity 3.56% -5.95%
Employees 1,100 -
CDP Score - -


3420 Central Expressway
United States - Map
+1-408-7315000 (Phone)
+1-408-7315380 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Affymetrix, Inc. (Affymetrix) is engaged in the development, manufacture, sale and service of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets. Affymetrix has developed its GeneChip system and related microarray technology as a platform for acquiring, analyzing and managing genetic information. The Company offers a line of products for two principal applications: genotyping and gene expression. Related microarray technology also offered by Affymetrix includes licenses for fabricating, scanning, collecting and analyzing results from complementary technologies. The Company also sells some of its products through life science supply specialists acting as authorized distributors in Latin America, India, the Middle East and Asia Pacific regions, including China. In October 2013, StoneCalibre announced that the completion of the acquisition of Anatrace, a part of Affymetrix, Inc.

Officers and directors

Stephen P. A. Fodor Ph.D. Executive Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Frank R. Witney Ph.D. President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Gavin Wood Chief Financial Officer, Executive Vice President
Age: 44
Bio & Compensation  - Reuters
Andrew J. Last Ph.D. Chief Operating Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
David Weber Executive Vice President, Chief Commercial Officer
Age: 60
Bio & Compensation  - Reuters
Robert P. Wayman Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Nelson C. Chan Independent Director
Age: 53
Bio & Compensation  - Reuters
Gary S. Guthart Ph.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Jami K. Nachtsheim Dover Independent Director
Age: 55
Bio & Compensation  - Reuters
Robert H. Trice Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters